Loading…
Fractyl Health, Inc. is projected to decline to $0.7557 by 2027, a -12% move from its current price of $0.8592. GUTS is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $0.8098 | $0.8593 | $0.9118 | +0.02% |
| May 30 | $0.7903 | $0.8595 | $0.9347 | +0.03% |
| May 31 | $0.7757 | $0.8596 | $0.9526 | +0.05% |
| Jun 1 | $0.7636 | $0.8597 | $0.968 | +0.06% |
| Jun 2 | $0.7531 | $0.8599 | $0.9818 | +0.08% |
| Jun 3 | $0.7437 | $0.86 | $0.9945 | +0.09% |
| Jun 4 | $0.7352 | $0.8601 | $1.01 | +0.11% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.7352 | $0.8601 | $1.01 | +0.11% |
| Week 2 | $0.6897 | $0.8611 | $1.08 | +0.22% |
| Week 3 | $0.6569 | $0.862 | $1.13 | +0.33% |
| Week 4 | $0.6305 | $0.863 | $1.18 | +0.44% |
| Week 5 | $0.6083 | $0.8639 | $1.23 | +0.55% |
| Week 6 | $0.5889 | $0.8649 | $1.27 | +0.66% |
| Week 7 | $0.5717 | $0.8658 | $1.31 | +0.77% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Fractyl Health, Inc. is a metabolic therapeutics company that develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.
The company also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients.
Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.
Fractyl Health, Inc. trades under the symbol GUTS. The stock is currently priced at $0.9096 and has a market capitalization of $144.31M, ranking 4041 by market cap.
Forecasts indicate a longer-term path of rising prices, with the 2030 average at $1.61 and the 2050 average at $6.71, and a 2050 max of $15.43.
The outlook includes a progression in sentiment from neutral in early years to bullish in later years, with an eventual strong upside implied by a 2050 average price of $6.71 and a maximum of $15.43, corresponding to a 637.6%ROI by 2050. The asset exhibits notable volatility, with an annualized volatility figure of 100% and a 30-day price range between $0.6066 and $1.36.
A major floor 60.9% below — a decisive break under it would weaken the trend.
The nearest floor, 40.2% below — buyers have tended to step in here.
The nearest ceiling, 11.0% above — a clean break opens room to run.
A major ceiling 153.7% above — clearing it would confirm fresh momentum.
Key GUTS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of GUTS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.9056 | Sell | $0.8864 | Sell |
| MA 10 | $0.8914 | Sell | $0.8659 | Sell |
| MA 20 | $0.8008 | Buy | $0.8055 | Buy |
| MA 50 | $0.6215 | Buy | $0.734 | Buy |
| MA 100 | $0.8235 | Buy | $0.8434 | Buy |
| MA 200 | $1.11 | Sell | $1.13 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 58.97 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | 42.84 | Neutral |
| Williams %R (14) | -43.18 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | 13.77 | Buy |
| Bollinger %B (20,2) | 0.64 | Neutral |
| Stochastic %K (14) | 56.82 | Neutral |
| TRIX (15) | 1.88 | Buy |
| Awesome (5,34) | 0.21 | Buy |
| Ultimate (7,14,28) | 54.94 | Neutral |
| Momentum (10) | 0.13 | Buy |
| Aroon Osc (25) | 68.00 | Buy |
| Hull MA (9) | 0.92 | Sell |
| ADX (14) | 31.59 | Buy |
| ATR (14) | 0.04 | Info |
The 30-day technical picture shows bullish sentiment in the near term, supported by an RSI of 70. The 50-day simple moving average sits at $0.6045 and the 200-day simple moving average at $1.11, providing nearby supports and resistances around these levels.
Key levels to watch are a support at $0.49 and a resistance at $0.954. The 30-day price range spans from $0.6066 to $1.36, indicating recent price activity within roughly a $0.75 band. The asset also shows high volatility, with an annualized volatility of 100%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.393 | $0.8592 | $1.27 | 0% | Neutral | |
| $0.5438 | $0.7557 | $1.14 | -12% | Neutral | |
| $0.7098 | $1.05 | $1.67 | +22% | Bullish | |
| $0.8636 | $1.34 | $2.25 | +56% | Bullish | |
| $0.8983 | $1.46 | $2.55 | +70% | Bullish | |
| $0.9735 | $1.65 | $2.98 | +93% | Bullish | |
| $0.8713 | $1.54 | $2.87 | +80% | Bullish | |
| $0.8119 | $1.50 | $2.86 | +74% | Bullish | |
| $0.8046 | $1.54 | $3.02 | +80% | Bullish | |
| $0.8942 | $1.78 | $3.57 | +108% | Bullish | |
| $1.02 | $2.28 | $5.01 | +165% | Bullish | |
| $2.64 | $5.86 | $13.47 | +582% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.393 | $0.8592 | $1.01 | +0.00% |
| June 2026 | $0.6828 | $0.8189 | $1.02 | -4.69% |
| July 2026 | $0.7146 | $0.8716 | $1.11 | +6.44% |
| August 2026 | $0.7525 | $0.9301 | $1.21 | +6.71% |
| September 2026 | $0.7196 | $0.8993 | $1.19 | -3.30% |
| October 2026 | $0.6991 | $0.8826 | $1.18 | -1.86% |
| November 2026 | $0.7306 | $0.9308 | $1.26 | +5.45% |
| December 2026 | $0.7196 | $0.9248 | $1.27 | -0.65% |
Click any year to see its month-by-month GUTS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect GUTS to range from $0.393 to $1.27 through 2026. The $0.8592 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The GUTS price prediction for 2027 points to an average of $0.7557 (low $0.5438, high $1.14) — a potential decline of -12% on today's $0.8592. A consolidation phase looks the most probable path here.
In 2028, GUTS is projected to trade between $0.7098 and $1.67, averaging $1.05 — a potential gain of +22% from today's $0.8592. That is up +39% on the projected 2027 average. Momentum favours further upside here.
Fractyl Health, Inc.'s 2029 outlook centres on $1.34, within a $0.8636 to $2.25 range. That is up +28% on the projected 2028 average. That marks a +56% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, GUTS could reach as high as $2.55, with a base case around $1.46 and support toward $0.8983 — roughly +70% from $0.8592. Momentum favours further upside here.
Expect GUTS to range from $0.9735 to $2.98 through 2031. The $1.65 average target implies a +93% move from current prices. That is up +13% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The GUTS price prediction for 2032 points to an average of $1.54 (low $0.8713, high $2.87) — a potential gain of +80% on today's $0.8592. Momentum favours further upside here.
In 2033, GUTS is projected to trade between $0.8119 and $2.86, averaging $1.50 — a potential gain of +74% from today's $0.8592. That is -3% versus the projected 2032 average. Buyers look set to stay in control over this stretch.
Fractyl Health, Inc.'s 2034 outlook centres on $1.54, within a $0.8046 to $3.02 range. That is up +3% on the projected 2033 average. That marks a +80% change versus current levels. Momentum favours further upside here.
By 2035, GUTS could reach as high as $3.57, with a base case around $1.78 and support toward $0.8942 — roughly +108% from $0.8592. Buyers look set to stay in control over this stretch.
Expect GUTS to range from $1.02 to $5.01 through 2040. The $2.28 average target implies a +165% move from current prices. That is up +28% on the projected 2035 average. Momentum favours further upside here.
The GUTS price prediction for 2050 points to an average of $5.86 (low $2.64, high $13.47) — a potential gain of +582% on today's $0.8592. Buyers look set to stay in control over this stretch.
Investing $1,000 in GUTS today (≈ 1,163.873371 GUTS) could be worth
$6,815.47
+$5,815.47 (+582%) by 2050 · US Dollar
Based on the average projected GUTS price of $5.86 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in GUTSwould be worth at today's price.
$1,000 invested in GUTS on May 27, 2025 (≈ 512.8205 GUTS) would be worth
$440.62
-$559.38 (-55.9%) today · 0.44× · US Dollar
Based on a GUTS entry price of $1.95 vs. today's $0.8592.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.921 | $932.9 | -6.7% |
| 1 month ago | $0.653 | $1,315.77 | +31.6% |
| 3 months ago | $0.475 | $1,808.84 | +80.9% |
| 6 months ago | $1.57 | $547.26 | -45.3% |
| 1 year ago | $1.95 | $440.62 | -55.9% |
| All time (2.3y) ago | $12.85 | $66.86 | -93.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our GUTS forecast.
Our base-case forecast reaches $1.70 around 2035.
Implied market cap at $1.70: $269.7M
The multi-year forecast shows a clear path of growth in average price from $0.9096 in 2026 to $6.71 in 2050, with a max of $15.43 and a 2050 ROI of 637.6%. In 2030, the average price is $1.61 with a 76.9% ROI, and by 2040 the average price reaches $2.65 with a 191.4% ROI, underscoring substantial long-term upside.
From 2028 onward, the sentiment is consistently bullish, with 2028 (avg $1.17, ROI 28.2%), 2029 (avg $1.48, ROI 63%), 2031 (avg $1.85, ROI 103.4%), and 2032–2035 showing continued gains. The forecast envisions continued upward movement into 2050 (avg $6.71, max $15.43, ROI 637.6%), but also notes earlier years with neutral to flat returns (e.g., 2026 ROI 0% and 2027 ROI -10.5%). These figures illustrate a wide potential range, reflecting uncertainty and risk alongside potential upside.
Tap a question to reveal the answer.
2030 avg $1.61; min $0.9886; max $2.81; ROI 76.9%; sentiment BULLISH.
Forecasts show bullish sentiment in later years with 2030 avg $1.61 and 2050 avg $6.71 with ROI up to 637.6%, but there is volatility and some years with neutral or negative returns (e.g., 2027 ROI -10.5%), so outcomes are uncertain and not guaranteed.
No. The forecasted 2040 max is $5.83, while the 2050 max is $15.43.
2026 min $0.393; avg $0.9096; max $1.34; ROI 0%; sentiment NEUTRAL.
Current price $0.9096; market cap $144.31M.
Fractyl Health, Inc. Community Discussion
0Share your Fractyl Health, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.